Tipifarnib in Head and Neck Squamous Cell Carcinoma With<i>HRAS</i>Mutations
Alan L. Ho(Memorial Sloan Kettering Cancer Center), Antonio Gualberto(Kura Oncology (United States)), Valentina Boni, Francis P. Worden(Georgetown University), David S. Hong(The University of Texas MD Anderson Cancer Center), Sung‐Bae Kim(Ulsan College), Sjoukje F. Oosting(University Medical Center Groningen), Jérôme Fayette(Université Claude Bernard Lyon 1), Ioanna Nixon(Beatson West of Scotland Cancer Centre), Myung‐Ju Ahn(Sungkyunkwan University), Nabil F. Saba(Emory University), Pol Specenier(Antwerp University Hospital), Deborah Jean Lee Wong(University of California, Los Angeles), Lisa Licitra(University of Milan), Catherine Scholz(Kura Oncology (United States)), Stephan Hackenberg(University of Würzburg), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Keith C. Bible(Mayo Clinic in Arizona), Irene Braña(Vall d'Hebron Institute of Oncology), Robert I. Haddad(Georgetown University), Mollie Leoni(Kura Oncology (United States)), Caroline Even(Institut Gustave Roussy), Binaifer Balsara(Kura Oncology (United States)), Jessica R. Bauman, Bridget Martell(Kura Oncology (United States)), M.J. Flor(Hospital Universitario Virgen del Rocío)
Cited by 196
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k